Moderate riskFDA DrugClass II

Paxil CR paroxetine tablets recalled for dissolution test failure

Apotex Corp. is recalling one lot of Paxil CR (paroxetine) 37.5mg extended-release tablets because the medication failed to meet dissolution specifications during 24-month stability testing. This means the tablets may not release the drug into the body as intended. The affected lot (TY9494, expiration 05/31/2027) was distributed nationwide.

From the FDA notice · Read the official notice ↗ · All Apotex recalls

What to do

  1. Check your Paxil CR bottle for lot number TY9494 with expiration date 05/31/2027.
  2. If you have this lot, contact your pharmacy or prescriber before stopping the medication.
  3. Do not stop taking paroxetine abruptly without medical guidance.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Paxil CR, Paroxetine, Extended-Release Tablets, 37.5mg, 30 count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario, Canada M9L 1T9, Manufactured for: Apotex Corp., Weston, Florida 33326, NDC 60505-4379-3
Sold in
Nationwide
Made for
Adults (0 months and older)

Details

Units affected
6,972 bottles
Illnesses reported
None reported
Manufactured in
2400 N Commerce Pkwy Ste 400, N/A, Weston, FL, United States
Classification
Class II
Recall number
D-0804-2026

In the FDA's words

Description
Paxil CR, Paroxetine, Extended-Release Tablets, 37.5mg, 30 count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario, Canada M9L 1T9, Manufactured for: Apotex Corp., Weston, Florida 33326, NDC 60505-4379-3 Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria Lot # TY9494, Exp Date: 05/31/2027. Distribution: US Nationwide. Affected quantity: 6,972 bottles
Hazard
Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

More from Apotex

See all

Related topics

PotencyDrugsSold nationwideMore from FDA Drug